Amneal Pharmaceuticals(AMRX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS ‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Af irms 2024 Full Year Guidance ‒ BRIDGEWATER, NJ, November 8, 2024 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2024. "Q3 was an excellent quarter where we continued to drive ...